No retraction, correction or concern found when last checked on Oct 23, 2026.

ACT001 attenuates microglia-mediated neuroinflammation after traumatic brain injury via inhibiting AKT/NFκB/NLRP3 pathway

Lin Cai, Qiuyuan Gong, Lin Qi and 13 more

Cell Communication and Signaling · 2022 · CC BY

Abstract

Background. Microglia-mediated neuroinflammatory response following traumatic brain injury (TBI) is considered as a vital secondary injury factor, which drives trauma-induced neurodegeneration and is lack of efficient treatment. ACT001, a sesquiterpene lactone derivative, is reportedly involved in alleviation of inflammatory response. However, little is known regarding its function in regulating innate immune response of central nervous system (CNS) after TBI. This study aimed to investigate the role and underlying mechanism of ACT001 in TBI.

Methods. Controlled cortical impact (CCI) models were used to establish model of TBI. Cresyl violet staining, evans blue extravasation, neurobehavioral function assessments, immunofluorescence and transmission electron microscopy were used to evaluate therapeutic effects of ACT001 in vivo. Microglial depletion was induced by administering mice with colony stimulating factor 1 receptor (CSF1R) inhibitor, PLX5622. Cell-cell interaction models were established as co-culture system to simulate TBI conditions in vitro. Cytotoxic effect of ACT001 on cell viability was assessed by cell counting kit-8 and activation of microglia cells were induced by Lipopolysaccharides (LPS). Pro-inflammatory cytokines expression was determined by Real-time PCR and nitric oxide production. Apoptotic cells were detected by TUNEL and flow cytometry assays. Tube formation was performed to evaluate cellular angiogenic ability. ELISA and western blot experiments were used to determine proteins expression. Pull-down assay was used to analyze proteins that bound ACT001.

Results. ACT001 relieved the extent of blood-brain barrier integrity damage and alleviated motor function deficits after TBI via reducing trauma-induced activation of microglia cells. Delayed depletion of microglia with PLX5622 hindered therapeutic effect of ACT001. Furthermore, ACT001 alleviated LPS-induced activation in mouse and rat primary microglia cells. Besides, ACT001 was effective in suppressing LPS-induced pro-inflammatory cytokines production in BV2 cells, resulting in reduction of neuronal apoptosis in HT22 cells and improvement of tube formation in bEnd.3 cells. Mechanism by which ACT001 functioned was related to AKT/NFκB/NLRP3 pathway. ACT001 restrained NFκB nuclear translocation in microglia cells through inhibiting AKT phosphorylation, resulting in decrease of NLRP3 inflammasome activation, and finally down-regulated microglial neuroinflammatory response.

Conclusions. Our study indicated that ACT001 played critical role in microglia-mediated neuroinflammatory response and might be a novel potential chemotherapeutic drug for TBI. Video Abstract

Supplementary Information. The online version contains supplementary material available at 10.1186/s12964-022-00862-y.

References 82

1.
Menon DK, Schwab K, Wright DW, Maas AI, Health DaCAWGotIaIItCDEfRoTBIaP. Position statement: definition of traumatic brain injury. Arch Phys Med Rehabil. 2010;91:1637–1640.
Not in our library10.1016/j.apmr.2010.05.017
2.
Mollayeva T, Mollayeva S, Colantonio A. Traumatic brain injury: sex, gender and intersecting vulnerabilities. Nat Rev Neurol. 2018;14:711-722.
Not in our library10.1038/s41582-018-0091-y
3.
Yang DX, Jing Y, Liu YL, Xu ZM, Yuan F, Wang ML, et al. Inhibition of transient receptor potential vanilloid 1 attenuates blood-brain barrier disruption after traumatic brain injury in mice. J Neurotrauma. 2019;36:1279-1290.
Not in our library10.1089/neu.2018.5942
4.
Smith DH, Meaney DF, Shull WH. Diffuse axonal injury in head trauma. J Head Trauma Rehabil. 2003;18:307-316.
Not in our library10.1097/00001199-200307000-00003
5.
Humble SS, Wilson LD, Wang L, Long DA, Smith MA, Siktberg JC, et al. Prognosis of diffuse axonal injury with traumatic brain injury. J Trauma Acute Care Surg. 2018;85:155-159.
Not in our library10.1097/ta.0000000000001852
6.
Stoica BA, Faden AI. Cell death mechanisms and modulation in traumatic brain injury. Neurotherapeutics. 2010;7:3-12.
Not in our library10.1016/j.nurt.2009.10.023
7.
Anti-inflammatory and immunomodulatory mechanisms of atorvastatin in a murine model of traumatic brain injury · 2017
No notice
8.
Capizzi A, Woo J, Verduzco-Gutierrez M. Traumatic brain injury: an overview of epidemiology, pathophysiology, and medical management. Med Clin North Am. 2020;104:213-238.
Not in our library10.1016/j.mcna.2019.11.001
9.
Shively SB, Priemer DS, Stein MB, Perl DP. Pathophysiology of traumatic brain injury, chronic traumatic encephalopathy, and neuropsychiatric clinical expression. Psychiatr Clin North Am. 2021;44:443-458.
Not in our library10.1016/j.psc.2021.04.003
10.
Loane DJ, Kumar A. Microglia in the TBI brain: the good, the bad, and the dysregulated. Exp Neurol. 2016;275(Pt 3):316-327.
Not in our library10.1016/j.expneurol.2015.08.018
11.
Microglial Activation in Traumatic Brain Injury · 2017
No notice
12.
Simon DW, McGeachy MJ, Bayir H, Clark RSB, Loane DJ, Kochanek PM. The far-reaching scope of neuroinflammation after traumatic brain injury. Nat Rev Neurol. 2017;13:572.
Not in our library10.1038/nrneurol.2017.116
13.
Roberts I, Yates D, Sandercock P, Farrell B, Wasserberg J, Lomas G, et al. Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial. Lancet. 2004;364:1321-1328.
Not in our library10.1016/s0140-6736(04)17188-2
14.
Skolnick BE, Maas AI, Narayan RK, van der Hoop RG, MacAllister T, Ward JD, et al. A clinical trial of progesterone for severe traumatic brain injury. N Engl J Med. 2014;371:2467-2476.
Not in our library10.1056/nejmoa1411090
15.
Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci. 2007;10:1387-1394.
Not in our library10.1038/nn1997
16.
Panday A, Inda ME, Bagam P, Sahoo MK, Osorio D, Batra S. Transcription factor NF-kappaB: an update on intervention strategies. Arch Immunol Ther Exp (Warsz). 2016;64:463-483.
Not in our library10.1007/s00005-016-0405-y
17.
Nathalie M, Polineni SP, Chin CN, Fawcett D, Clervius H, Maria QSL, et al. Targeting microglial polarization to improve TBI outcomes. CNS Neurol Disord Drug Targets. 2021;20:216-227.
Not in our library10.2174/1871527319666200918145903
18.
Brown GC, Vilalta A, Fricker M. Phagoptosis—cell death by phagocytosis—plays central roles in physiology, host defense and pathology. Curr Mol Med. 2015;15:842-851.
Not in our library10.2174/156652401509151105130628
19.
Ramlackhansingh AF, Brooks DJ, Greenwood RJ, Bose SK, Turkheimer FE, Kinnunen KM, et al. Inflammation after trauma: microglial activation and traumatic brain injury. Ann Neurol. 2011;70:374-383.
Not in our library10.1002/ana.22455
20.
Shlosberg D, Benifla M, Kaufer D, Friedman A. Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury. Nat Rev Neurol. 2010;6:393-403.
Not in our library10.1038/nrneurol.2010.74
21.
Microglial neuroinflammation contributes to tau accumulation in chronic traumatic encephalopathy · 2016
No notice
22.
Gasparini C, Feldmann M. NF-kappaB as a target for modulating inflammatory responses. Curr Pharm Des. 2012;18:5735-5745.
Not in our library10.2174/138161212803530763
23.
Mincheva-Tasheva S, Soler RM. NF-kappaB signaling pathways: role in nervous system physiology and pathology. Neuroscientist. 2013;19:175-194.
Not in our library10.1177/1073858412444007
24.
Cellular Specificity of NF-κB Function in the Nervous System · 2019
No notice
25.
Zhang Q, Lu Y, Ding Y, Zhai J, Ji Q, Ma W, et al. Guaianolide sesquiterpene lactones, a source to discover agents that selectively inhibit acute myelogenous leukemia stem and progenitor cells. J Med Chem. 2012;55:8757-8769.
Not in our library10.1021/jm301064b
26.
An Y, Guo W, Li L, Xu C, Yang D, Wang S, et al. Micheliolide derivative DMAMCL inhibits glioma cell growth in vitro and in vivo. PLoS ONE. 2015;10:e0116202.
Not in our library10.1371/journal.pone.0116202
27.
Jaffar J, Glaspole I, Symons K, Westall G. Inhibition of NF-kappaB by ACT001 reduces fibroblast activity in idiopathic pulmonary fibrosis. Biomed Pharmacother. 2021;138:111471.
Not in our library10.1016/j.biopha.2021.111471
28.
Liu Q, Zhang S, Zhu D, Tang X, Che Y, Feng X. The parthenolide derivative ACT001 synergizes with low doses of L-DOPA to improve MPTP-induced Parkinson's disease in mice. Behav Brain Res. 2020;379:112337.
Not in our library10.1016/j.bbr.2019.112337
29.
Viennois E, Xiao B, Ayyadurai S, Wang L, Wang PG, Zhang Q, et al. Micheliolide, a new sesquiterpene lactone that inhibits intestinal inflammation and colitis-associated cancer. Lab Investig. 2014;94:950-965.
Not in our library10.1038/labinvest.2014.89
30.
Ghantous A, Gali-Muhtasib H, Vuorela H, Saliba NA, Darwiche N. What made sesquiterpene lactones reach cancer clinical trials? Drug Discov Today. 2010;15:668-678.
Not in our library10.1016/j.drudis.2010.06.002
31.
Sesquiterpene Lactones from Artemisia Genus: Biological Activities and Methods of Analysis · 2015
No notice
32.
Hehner SP, Heinrich M, Bork PM, Vogt M, Ratter F, Lehmann V, et al. Sesquiterpene lactones specifically inhibit activation of NF-kappa B by preventing the degradation of I kappa B-alpha and I kappa B-beta. J Biol Chem. 1998;273:1288-1297.
Not in our library10.1074/jbc.273.3.1288
33.
Saadane A, Masters S, DiDonato J, Li J, Berger M. Parthenolide inhibits IkappaB kinase, NF-kappaB activation, and inflammatory response in cystic fibrosis cells and mice. Am J Respir Cell Mol Biol. 2007;36:728-736.
Not in our library10.1165/rcmb.2006-0323oc
34.
Jin P, Madieh S, Augsburger LL. The solution and solid state stability and excipient compatibility of parthenolide in feverfew. AAPS PharmSciTech. 2007;8:E105.
Not in our library10.1208/pt0804105
35.
Xi XN, Liu N, Wang QQ, Wu HT, He HB, Wang LL, et al. Pharmacokinetics, tissue distribution and excretion of ACT001 in Sprague-Dawley rats and metabolism of ACT001. J Chromatogr B Analyt Technol Biomed Life Sci. 2019;1104:29-39.
Not in our library10.1016/j.jchromb.2018.11.004
36.
Li Q, Sun Y, Liu B, Li J, Hao X, Ge W, et al. ACT001 modulates the NF-kappaB/MnSOD/ROS axis by targeting IKKbeta to inhibit glioblastoma cell growth. J Mol Med (Berl). 2020;98:263-277.
Not in our library10.1007/s00109-019-01839-0
37.
Lickliter JD, Jennens R, Lemech CR, Su SYC, Chen Y. Phase 1 dose-escalation study of ACT001 in patients with recurrent glioblastoma and other advanced solid tumors. J Clin Oncol. 2018;36:e14048-e14048.
Not in our library10.1200/jco.2018.36.15_suppl.e14048
38.
ACT001, a novel PAI-1 inhibitor, exerts synergistic effects in combination with cisplatin by inhibiting PI3K/AKT pathway in glioma · 2019
No notice
39.
ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma · 2020
No notice
40.
Tamashiro TT, Dalgard CL, Byrnes KR. Primary microglia isolation from mixed glial cell cultures of neonatal rat brain tissue. J Vis Exp. 2012:e3814.
Not in our library10.3791/3814

All 82 references

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.